|Description||Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cytokine-mediated lymphocyte proliferation. Everolimus can be used as an immunosuppressant in the treatment of renal cell cancer and other cancers.|
|Brife Description||inhibitor of mTOR, immunosuppressant|
|Appearance||Off-White to Pale Yellow Solid|
|Synonyms||Afinitor; Certican; Zortress; RAD001; SDZ-RAD; 40-O-(2-Hydroxyethyl)rapamycin; 42-O-(2-Hydroxy)ethyl Rapamycin|
|Solubility||Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility.|
|Shelf Life||2 years|
|Melting Point||107-113 °C|
ABTL-0812 is an orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR), rictor-mTOR and dihydrofolate reductase with p...
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. AZD2014 inhibits the activity o...
Ridaforolimus is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus bin...
mTOR activator with an inhibitory effect on autophagy. MHY1485 markedly increased the LC3II/LC3I ratio dose-dependently and time-dependently by inhibition of th...
PI3K inhibitory activity. Inhibits voltage-gated Kv channel activity (IC50 = 64.6 μM). Various pharmacological effects including inhibition of LPS-stimulated FP...
Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively.
AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...
SC-III3 is a scopoletin derivative and has been found to induce the autophagy of hepatoma HepG2 cells so that could be significant in anticancer studies.
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cyto...
PP242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM. PP242 also shows residual (micromolar) activity against panel of tyrosine kinases. Bu...
The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiase...
Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM.
Dactolisib, also known as BEZ235, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BEZ235 speci...
The hydrochloride salt form of CC-115 which is a mTOR / DNA-PK inhibitor that probably has antineoplastic effect through influencing the cellular proliferation ...
GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively...
Perhexiline maleate salt
Perhexiline maleate salt is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor. It is an anti-anginal metabolic modulator and used in treatments for a...
WYE-125132, also known as WYE-132, is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor. WYE-132 inhibited mTORC1 and mTORC2 in diverse canc...
Apitolisib, also known as GDC-0980 and RG7422; or GNE390, is a dual PI3 kinase/mTOR inhibitor, is also an orally available agent targeting phosphatidylinosit...
SMER18 is a small molecule enhancer of rapamycin. It act as a mTOR-independent autophagy inducer. It is a positive regulators of autophagy acting independently ...
MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...